The big picture: Walmart is significantly enhancing its employee benefits package for 2027, introducing no-cost coverage for over 250 prescription drugs, expanded specialist care access, and increased neonatal intensive care unit (NICU) leave.

Why it matters: This move by the largest private employer in the U.S. sets a new benchmark for corporate benefits, influencing retention strategies and healthcare coverage decisions across the retail and logistics sectors.

Between the lines:

• Walmart will cover certain GLP-1 medications (Ozempic, Mounjaro) for Type 2 diabetes, but not for weight loss, requiring prior authorization.
• Specialist care for serious conditions will expand through partnerships with Mayo Clinic and Cleveland Clinic.
• New parents will receive up to 12 weeks of paid NICU leave, stackable with existing parental leave.

Staffing & HR impact: These enhanced benefits are a direct investment in employee retention, aiming to reduce costly turnover in a competitive labor market and potentially influencing other large employers' benefits offerings. The strategic exclusion of weight-loss GLP-1 coverage highlights a nuanced approach to managing healthcare costs while still attracting and retaining talent.

The bottom line: Walmart's proactive benefits overhaul signals a long-term strategy to stabilize its workforce and manage healthcare expenditures, offering a blueprint for other companies navigating similar challenges.